REGENXBIO Inc. (RGNX)
- Previous Close
15.80 - Open
16.09 - Bid 16.19 x 100
- Ask 16.24 x 100
- Day's Range
16.01 - 16.85 - 52 Week Range
11.83 - 28.80 - Volume
390,854 - Avg. Volume
653,644 - Market Cap (intraday)
799.425M - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-- - EPS (TTM)
-5.87 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.08
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
www.regenxbio.comRecent News: RGNX
Performance Overview: RGNX
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGNX
Valuation Measures
Market Cap
778.24M
Enterprise Value
526.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.07
Price/Book (mrq)
1.99
Enterprise Value/Revenue
6.07
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-299.97%
Return on Assets (ttm)
-23.60%
Return on Equity (ttm)
-60.80%
Revenue (ttm)
86.73M
Net Income Avi to Common (ttm)
-260.15M
Diluted EPS (ttm)
-5.87
Balance Sheet and Cash Flow
Total Cash (mrq)
338.7M
Total Debt/Equity (mrq)
43.66%
Levered Free Cash Flow (ttm)
-107.17M
Research Analysis: RGNX
Company Insights: RGNX
RGNX does not have Company Insights